Table 1 Drug screens using organoids

Breast cancer

[28]

Afatinib AZD8055 everolimus GDC-0068 gefitinib pictilisib

Clear cell renal cancer

[46]

Cabozantinib foretinib levantinib + everolimus sunitinib SU11274 tensirolimus

Colorectal cancer

[29]

ABT-263 AICAR AKT inhibitor VIII AMG-706 axitinib AZ960 AZD-2281 AZD6482 AZD8055 AZD8931 BI-2536 BIBW2992 BIRB-0796 BMN-673 BMS-345541 BMS-536924 BMS-708163 bortezomib BX-795 BYL719 camptothecin CEP-701 cetuximab CHIR-99021 cisplatin dabrafenib dasatanib docetaxel EHT-1864 embelin FK866 fulvestrant GDC-0449 GDC0941 gefitinib gemcitibine GSK269962A GW-441756 INCB-18424 irinotecan-trihydrochloride JNJ-26854165 JNK-inhibitor-VIII JQ1 KU-55933 lenalidomide LY317615 mirin MK-2206 MLN8237 nilotinib NU-7441 nutlin-3a NVP-BEZ235 obatoclax-mesylate OSI-906 oxaliplatin PAC-1 paclitaxel PD-0332991 PD-173074 PF-02341066 PF-4708671 PF477736 PF-562271 PLX4720 RO-3306SB-216763 SB-505124 SCH772984 SGC0946 SL-0101-1 sorafenib temozolomide trametanib UNC0642 vorinostat XAV-939 YK-4-279 ZM-447439 17-AAG 5-fluorouracil (5Z)-7-oxozeaenol 681640

Colorectal cancer

[47]

Afatinib AKT inhibitor VIII doxorubicin MEK1/2 inhibitor III nutlin-3a 5-fluorouracil

7-Ethyl-10-hydroxycamptothecin (SN-38)

Liver cancer

[6]

AZD8931^a axitinib BIRB-0796 BIRB-1532 CH5424802 cisplatin dabrafenib dasatanib^a deltarasin doxorubicin EMD-1214063 gemcitibine^a GSK126 KU-55933 lapatinib LGK974 LY2109761 MK-2206 nutlin-3a olaparib OSI-027 PD-0332991 PD-173074 SCH772984^a sorafenib taselisib^a trametinib vorinostat 5-fluorouracil

Prostate cancer

[27]

BKM-120 enzalutamide everolimus

Ovarian cancer

[33]

Azacytidine AZD2014 AZD5363 belinostat BKM120 carboplatin cyclopamine DAPT dasatinib decitabine doxorubicin ICG-001 MK-5108 NSC23766 olaparib paclitaxel temsirolimus